AI-Bio is located in the Linping Economic and Technological Development Zone, Hangzhou. With a focus on addressing critical clinical needs in oncology, central nervous system (CNS) disorders, and autoimmune- inflammatory diseases that remain unsolved, the company is driven by technological innovation and centered on precise drug design. By integrating advanced technologies and strategies in artificial intelligence, medicinal chemistry, and biology, AI-Bio is dedicated to develope innovative drugs with novel mechanisms of action and outstanding clinical value.

Led by experts from internationally renowned pharmaceutical companies, senior engineers, and a team of Ph.D. professionals, AI-Bio brings together specialists in computational chemistry, medicinal chemistry, pharmacology and toxicology, pharmaceutical analysis, pharmacokinetics, and pharmaceutics, to  establish an advanced preclinical drug development platform with a well-structured team, which enables the discovery of novel targets, lead compound identification and optimization, pharmacodynamic and pharmacokinetic evaluation, safety assessment, candidate molecule validation, and preclinical pharmaceutical research.

Key Research Areas:

1. Innovative drug development for oncology

2. Innovative drug development for immune-inflammatory diseases

3. Innovative drug development for central nervous system (CNS) disorders

Guided by the philosophy of "Decoding Mysteries in Life, Shaping Our Future for Health" and driven by the vision of "AI-Empowered Discovery, Life Protected Comprehensively“, AI-Bio strives to become a cutting-edge AI-driven pharmaceutical company with a distinctive identity and forward-looking view.